Grail Partners with Epic to Promote Galleri Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy GRAL?
Grail announced a collaboration with Epic to bring the Galleri multi-cancer early detection test into one of the nation's most widely used electronic health record platforms, supporting broader adoption across health systems in the United States. Epic is an EHR platform used by many of the largest and most advanced health systems. Integration through Epic Aura will allow interested health systems and their healthcare providers to order the Galleri test directly at the point of care, receive results, and manage patient follow-up seamlessly within their existing native EHR and within their existing clinical workflows. Through this integration, clinicians using Epic can access the Galleri test within their native EHR environment, helping to eliminate administrative burden, reduce manual processes, and improve the overall provider and patient experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 51.710
Low
38.00
Averages
60.86
High
83.71
Current: 51.710
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL Shares Decline After Neutral Ratings from Analysts
- Rating Downgrade Impact: GRAIL's shares fell on Friday after Mizuho Securities and Piper Sandler initiated coverage with Neutral ratings, indicating a decline in market confidence regarding its multi-cancer early detection test, Galleri.
- Trial Setback: The large clinical trial conducted within the U.K. National Health Service, involving over 140,000 participants, failed to meet its primary goal, which analysts suggest could hinder future competitive positioning in the market.
- Price Target Setting: Mizuho set a price target of $58, while Piper set it at $54, both expressing caution about Galleri's market outlook and suggesting that significant growth in MCED volume may not occur until 2027, post-FDA approval.
- Market Outlook Monitoring: Analysts noted that while GRAIL holds the largest clinical datasets in the multi-cancer early detection space, early feedback raises questions about its competitive advantage, making the evolution of reimbursement and regulatory pathways critical to watch.
See More
Investigation Launched into GRAIL, Inc. Securities Violations
- Investigation Initiated: The Schall Law Firm has announced an investigation into GRAIL, Inc. to determine potential violations of securities laws, particularly regarding whether the company issued false or misleading statements that could affect investor rights.
- Trial Results Disappoint: GRAIL's announcement on February 19, 2026, regarding the NHS-Galleri trial revealed that no statistically significant reduction in Stage III-IV was observed, leading to a sharp decline in the company's stock price and raising concerns about its future prospects.
- Investor Losses: Following the disappointing trial results, shareholders of GRAIL are facing potential losses, prompting the Schall Law Firm to encourage affected investors to participate in the investigation to protect their legal rights.
- Legal Services Offered: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering free consultations to assist global investors in addressing legal issues and safeguarding their investment interests.
See More
GRAIL Partners with Epic to Enhance Galleri Test Access
- Integration Advantage: GRAIL's collaboration with Epic will enable approximately 450 health systems to access Galleri test results within existing patient portals, streamlining the early cancer detection process and enhancing the efficiency and quality of healthcare services.
- Clinical Application Facilitation: The Epic Aura platform allows clinicians to seamlessly order the Galleri multi-cancer early detection test at the point of care, reducing administrative burdens and optimizing patient follow-up management, which is expected to significantly increase screening adoption rates.
- Implementation Planning Initiated: Implementation planning began in Q1 2026, with GRAIL working closely with Epic and AWS to ensure the success of early adopter programs, aiming for broad availability by the end of 2026 to further integrate early cancer screening.
- Survival Rate Improvement Goal: GRAIL aims to lower operational barriers through its partnership with Epic, making it easier to incorporate the Galleri test into routine care, ultimately supporting early cancer detection before symptoms appear and improving cancer survival rates.
See More
Iran Conflict Raises Recession Risks Amid Inflation
- Recession Risk: The ongoing conflict in Iran is causing inflationary pressures from soaring energy and food prices, complicating global economic challenges and increasing investor interest in healthcare stocks as a defensive measure.
- Defensive Healthcare Stocks: Large-cap pharmaceutical company Johnson & Johnson (JNJ) and integrated healthcare company CVS Health are viewed as defensive stocks, with JNJ's beta at 0.33 and CVS at 0.46, indicating their relative stability during economic downturns.
- Opportunities in Small-Cap Stocks: Investors may consider small- and mid-cap healthcare companies whose growth relies on binary events like clinical trial results, as successful firms can offset losses from others, despite the inherent risks.
- Investment Strategy Choices: Risk-averse investors may prefer low-beta defensive stocks, while risk-seeking investors might opt for high-risk, high-reward healthcare stocks to navigate potential recessionary pressures.
See More
Grail Partners with Superpower for Multi-Cancer Early Detection Test
- Partnership Announcement: Grail has partnered with preventative health platform Superpower to provide the Galleri multi-cancer early detection test, aiming to enhance the effectiveness of cancer screenings, particularly in early detection.
- Detection Capabilities: The Galleri test can detect signals from over 50 types of cancer and predict the origin of these signals, offering patients a more precise early diagnosis that could significantly improve treatment success rates.
- Research Findings: Grail's PATHFINDER-2 study found that incorporating Galleri into recommended cancer screenings boosted cancer detection rates more than seven-fold, a significant increase that could lead to earlier cancer discovery and better patient outcomes.
- Market Response: Despite facing market challenges, including rating downgrades and leadership transitions, the collaboration with Superpower may be viewed as a strategic opportunity to enhance market competitiveness through innovative detection technologies.
See More
Superpower Partners with GRAIL to Launch Cancer Screening
- Strategic Partnership: Superpower has formed a strategic partnership with GRAIL to introduce the Galleri® multi-cancer early detection test, aiming to enhance public health management by breaking down traditional barriers to cancer screening and making it more accessible.
- Current Detection Landscape: Cancer remains the second leading cause of death in the U.S., with an estimated 40% of Americans expected to be diagnosed in their lifetime, while existing screening standards only cover five cancer types, resulting in nearly 86% of cancers going undetected, highlighting the urgent need for innovative detection methods.
- Significant Detection Improvement: GRAIL's PATHFINDER 2 study demonstrated that integrating the Galleri test with standard screenings increased cancer detection rates by over seven-fold, with more than half of detected cancers identified at stages I or II, where treatment outcomes are typically better.
- Employer Health Management: This partnership provides employers with a critical health management tool, combining multi-cancer early detection with comprehensive biomarker testing to help identify health risks before they escalate into high-cost events, thereby improving employee health outcomes.
See More
GRAIL Shares Decline After Neutral Ratings from Analysts
- Rating Downgrade Impact: GRAIL's shares fell on Friday after Mizuho Securities and Piper Sandler initiated coverage with Neutral ratings, indicating a decline in market confidence regarding its multi-cancer early detection test, Galleri.
- Trial Setback: The large clinical trial conducted within the U.K. National Health Service, involving over 140,000 participants, failed to meet its primary goal, which analysts suggest could hinder future competitive positioning in the market.
- Price Target Setting: Mizuho set a price target of $58, while Piper set it at $54, both expressing caution about Galleri's market outlook and suggesting that significant growth in MCED volume may not occur until 2027, post-FDA approval.
- Market Outlook Monitoring: Analysts noted that while GRAIL holds the largest clinical datasets in the multi-cancer early detection space, early feedback raises questions about its competitive advantage, making the evolution of reimbursement and regulatory pathways critical to watch.
See More
Investigation Launched into GRAIL, Inc. Securities Violations
- Investigation Initiated: The Schall Law Firm has announced an investigation into GRAIL, Inc. to determine potential violations of securities laws, particularly regarding whether the company issued false or misleading statements that could affect investor rights.
- Trial Results Disappoint: GRAIL's announcement on February 19, 2026, regarding the NHS-Galleri trial revealed that no statistically significant reduction in Stage III-IV was observed, leading to a sharp decline in the company's stock price and raising concerns about its future prospects.
- Investor Losses: Following the disappointing trial results, shareholders of GRAIL are facing potential losses, prompting the Schall Law Firm to encourage affected investors to participate in the investigation to protect their legal rights.
- Legal Services Offered: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering free consultations to assist global investors in addressing legal issues and safeguarding their investment interests.
See More
GRAIL Partners with Epic to Enhance Galleri Test Access
- Integration Advantage: GRAIL's collaboration with Epic will enable approximately 450 health systems to access Galleri test results within existing patient portals, streamlining the early cancer detection process and enhancing the efficiency and quality of healthcare services.
- Clinical Application Facilitation: The Epic Aura platform allows clinicians to seamlessly order the Galleri multi-cancer early detection test at the point of care, reducing administrative burdens and optimizing patient follow-up management, which is expected to significantly increase screening adoption rates.
- Implementation Planning Initiated: Implementation planning began in Q1 2026, with GRAIL working closely with Epic and AWS to ensure the success of early adopter programs, aiming for broad availability by the end of 2026 to further integrate early cancer screening.
- Survival Rate Improvement Goal: GRAIL aims to lower operational barriers through its partnership with Epic, making it easier to incorporate the Galleri test into routine care, ultimately supporting early cancer detection before symptoms appear and improving cancer survival rates.
See More
Iran Conflict Raises Recession Risks Amid Inflation
- Recession Risk: The ongoing conflict in Iran is causing inflationary pressures from soaring energy and food prices, complicating global economic challenges and increasing investor interest in healthcare stocks as a defensive measure.
- Defensive Healthcare Stocks: Large-cap pharmaceutical company Johnson & Johnson (JNJ) and integrated healthcare company CVS Health are viewed as defensive stocks, with JNJ's beta at 0.33 and CVS at 0.46, indicating their relative stability during economic downturns.
- Opportunities in Small-Cap Stocks: Investors may consider small- and mid-cap healthcare companies whose growth relies on binary events like clinical trial results, as successful firms can offset losses from others, despite the inherent risks.
- Investment Strategy Choices: Risk-averse investors may prefer low-beta defensive stocks, while risk-seeking investors might opt for high-risk, high-reward healthcare stocks to navigate potential recessionary pressures.
See More
Grail Partners with Superpower for Multi-Cancer Early Detection Test
- Partnership Announcement: Grail has partnered with preventative health platform Superpower to provide the Galleri multi-cancer early detection test, aiming to enhance the effectiveness of cancer screenings, particularly in early detection.
- Detection Capabilities: The Galleri test can detect signals from over 50 types of cancer and predict the origin of these signals, offering patients a more precise early diagnosis that could significantly improve treatment success rates.
- Research Findings: Grail's PATHFINDER-2 study found that incorporating Galleri into recommended cancer screenings boosted cancer detection rates more than seven-fold, a significant increase that could lead to earlier cancer discovery and better patient outcomes.
- Market Response: Despite facing market challenges, including rating downgrades and leadership transitions, the collaboration with Superpower may be viewed as a strategic opportunity to enhance market competitiveness through innovative detection technologies.
See More
Superpower Partners with GRAIL to Launch Cancer Screening
- Strategic Partnership: Superpower has formed a strategic partnership with GRAIL to introduce the Galleri® multi-cancer early detection test, aiming to enhance public health management by breaking down traditional barriers to cancer screening and making it more accessible.
- Current Detection Landscape: Cancer remains the second leading cause of death in the U.S., with an estimated 40% of Americans expected to be diagnosed in their lifetime, while existing screening standards only cover five cancer types, resulting in nearly 86% of cancers going undetected, highlighting the urgent need for innovative detection methods.
- Significant Detection Improvement: GRAIL's PATHFINDER 2 study demonstrated that integrating the Galleri test with standard screenings increased cancer detection rates by over seven-fold, with more than half of detected cancers identified at stages I or II, where treatment outcomes are typically better.
- Employer Health Management: This partnership provides employers with a critical health management tool, combining multi-cancer early detection with comprehensive biomarker testing to help identify health risks before they escalate into high-cost events, thereby improving employee health outcomes.
See More
